2013 American Transplant Congress
Anti-TIM-4 Mediates Long-Term Engraftment of Islet Allografts by Promoting IL-10 Expression by TIM-1+ Bregs and Inhibiting IFNγ Expression by Proinflammatory “Be1” B Cells
University of Pittsburgh, Pittsburgh; Harvard Medical School, Boston
We recently defined TIM-1 as an inclusive marker for IL-10 expressing regulatory B cells (Bregs). Moreover, Α-TIM-1 mAb prolongs allograft survival (GS) through induction of…2013 American Transplant Congress
Monotherapy with HuABC2, a Novel Humanized Antibody Against CD122 (The IL-2/IL-15 Receptor β Chain), Prolongs the Survival Times of Non-Human Primate (NHP) Recipients of Life-Sustaining Renal Allografts
Background: CD122 is the Β chain of the receptors for IL-2 and IL-15, two key cytokines implicated in transplant rejection. HuABC2 (humanized IgG1, kappa) is…2013 American Transplant Congress
Delayed HCC MELD Exception Score Improves Disparity in Access to Liver Transplant
Background: In the US, wait-list dropout is lower and the transplant rate higher for candidates with standard MELD exception for hepatocellular carcinoma (HCC) than for…2013 American Transplant Congress
Choice of Induction Therapy in Kidney Transplant: It’s Race Not PRA
Background: rATG and IL-2RA are the most common induction agents used for KTX. There is no consensus on choice of induction. The aim of this…2013 American Transplant Congress
Genetic Adaptation of Polyomavirus BK (BKV) to Immunologic and Pharmacologic Selection Pressure
BACKGROUND: Characterizing the genomic plasticity of BKV will further our understanding of viral epidemiology, diagnosis, and clinical outcome, and facilitate development of vaccines and drug…2013 American Transplant Congress
FL/G-CSF/AMD3100 Mobilized Hematopoietic Stem Cells Induce Mixed Chimerism with Nonmyeloablative Conditioning and Transplantation Tolerance without GVHD
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
Mobilized hematopoietic stem cells (HSC) now serve as a major source for transplantation. Better mobilizing approaches are clinically important. AMD3100, a CXCR4 competitive inhibitor, has…2013 American Transplant Congress
Experience with Linezolid (LZD) for the Treatment of Nocardiosis in Solid Organ Transplant Recipients (SOT)
University of Pittsburgh Medical Center, Pittsburgh; Affiliated Community Medical Centers, Willmar
Objectives: Combination therapy including amikacin is recommended for the treatment of severe Nocardia infections. Use of amikacin in SOT is difficult due to renal dysfunction…2013 American Transplant Congress
Effects of Locoregional Treatment and “Downstaging” on Long-Term Post-Liver Transplant Outcomes for Patients with Hepatocellular Carcinoma
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Research, UNOS, Richmond, VA
IntroductionLocoregional therapy (LRT) has been used to stabilize tumor growth for patients with hepatocellular carcinoma (HCC) waiting for liver transplantation (LT). However, the long-term effects…2013 American Transplant Congress
Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: 5 Years Follow-Up of the ZEUS Trial
ZEUS Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Aim: To follow-up (FU) on renal function (RF), efficacy and safety after conversion to an Everolimus (EVE)/Enteric-Coated Mycophenolate Sodium (EC-MPS) regimen after cyclosporine A (CsA)…2013 American Transplant Congress
Tauroursodeoxycholic Acid Alleviate Ischemia-Reperfusion Injury in Donation after Cardiac Death Liver Transplantation
Background Donation after Cardiac Death (DCD) liver graft can provide possible and practical solutions to the organ shortage crisis, but extended warm ischemia time aggravates…
- « Previous Page
- 1
- …
- 147
- 148
- 149
- 150
- 151
- …
- 178
- Next Page »